Kanjinti Drug Interactions: 13 Major, 291 Moderate
Kanjinti (Trastuzumab-Anns) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Kanjinti. Always confirm against the full prescribing information.
100 interactions
Abatacept
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Abatacept.
Level 1 evidence
Adalimumab
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Adalimumab.
Level 1 evidence
Alclometasone
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Alclometasone.
Level 1 evidence
Aldesleukin
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Aldesleukin.
Level 1 evidence
Alemtuzumab
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Alemtuzumab.
Level 1 evidence
Amcinonide
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Amcinonide.
Level 1 evidence
Anakinra
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Anakinra.
Level 1 evidence
Anastrozole
The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Anastrozole.
Level 2 evidence
Anifrolumab
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Anifrolumab.
Level 1 evidence
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trastuzumab.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Antilymphocyte immunoglobulin (horse).
Level 1 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Antithymocyte immunoglobulin (rabbit).
Level 1 evidence
Enter your NPI to unlock 2 major interactions for Kanjinti
Kanjinti (Trastuzumab-Anns) has 811 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Kanjinti (Trastuzumab-Anns) has 13 major, 291 moderate, and 507 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Kanjinti. Always confirm against the full prescribing information.